New Generation Coronary Stent Technology-Is the Future Biodegradable?

Heart Lung and Circulation

Volumn 22, Issue 7, 2013, Pages 495-506

  Sammel, Anthony M ^a   Chen, Daniel ^a   Jepson, Nigel ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Absorbable implant; Biodegradable stent; Coronary restenosis; Drug eluting stents; Polymers; Thrombosis

Indexed keywords

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MAGNESIUM; MYOLIMUS; NOVOLIMUS; PACLITAXEL; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; POVIDONE; PROBUCOL; TISSUE SCAFFOLD; UMIROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS;

BARE METAL STENT; BIOCOMPATIBILITY; BIODEGRADABILITY; CORONARY STENT; DRUG EFFECT; DRUG ELUTING STENT; EQUIPMENT DESIGN; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; IN-STENT RESTENOSIS; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THERAPY EFFECT;

ABSORBABLE IMPLANTS; ANIMALS; CLINICAL TRIALS AS TOPIC; COATED MATERIALS, BIOCOMPATIBLE; CORONARY VESSELS; HUMANS; STENTS;

EID: 84879506060     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2013.02.008     Document Type: Review

References (82)

1. von Birgelen C., Basalus M.W.Z., Tandjung K., van Houwelingen K.G., Stoel M.G., Louwerenburg J.H.W., et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol 2012, 59:1350-1361.
2. Mintz G.S., Popma J.J., Pichard A.D., Kent K.M., Satler L.F., Wong C., et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996, 94:35-43.
3. Serruys P.W., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994, 331:489-495.
4. Serruys P.W., Kutryk M.J.B., Ong A.T.L. Coronary-artery stents. N Engl J Med 2006, 354:483-495.
5. Morice M.-C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773-1780.
6. Garg S., Serruys P.W. Coronary stents: looking forward. J Am Coll Cardiol 2010, 56:S43-S78.
7. Ko B.S., Meredith I.T. New DES: a new step forward?. Minerva Cardioangiol 2012, 60:41-56.
8. Alfonso F., Fernandez C. Second-generation drug-eluting stents. Moving the field forward. J Am Coll Cardiol 2011, 58:26-29.
9. Stone G.W., Rizvi A., Sudhir K., Newman W., Applegate R.J., Cannon L.A., et al. Randomized comparison of everolimus- and paclitaxel-eluting stents, 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol 2011, 58:19-25.
10. Smits P.C., Kedhi E., Royaards K.-J., Joesoef K.S., Wassing J., Rademaker-Havinga T.A.M., et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial). J Am Coll Cardiol 2011, 58:11-18.
11. Jensen L.O., Thayssen P., Hansen H.S., Christiansen E.H., Tilsted H.H., Krusell L.R., et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 2012, 125:1246-1255.
12. de Waha A., Dibra A., Byrne R.A., Ndrepepa G., Mehilli J., Fusaro M., et al. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. Circulation 2011, 4:371-377.
13. Rasmussen K., Maeng M., Kaltoft A., Thayssen P., Kelbaek H., Tilsted H.H., et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010, 375:1090-1099.
14. Park D.-W., Kim Y.-H., Yun S.-C., Kang S.-J., Lee S.-W., Lee C.-W., et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol 2010, 56:1187-1195.
15. Raber L., Magro M., Stefanini G.G., Kalesan B., van Domburg R.T., Onuma Y., et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012, 125:1110-1121.
16. Stone G.W., Witzenbichler B., Guagliumi G., Peruga J.Z., Brodie B.R., Dudek D., et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011, 377:2193-2204.
17. Stefanini G.G., Kalesan B., Serruys P.W., Heg D., Buszman P., Linke A., et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011, 378:1940-1948.
18. Holmes D.R., Louis A.C., Cannon A.D., Stahle E., Morice M.-C., Mack M.J., et al. Four-year follow-up of the SYNTAX trial: optimal revascularization strategy in patients with three-vessel disease and/or left main disease. Presented at Transcatheter Cardiovascular Therapeutics 2011, Available at http://wwwsyntaxscorecom/indexphp?option=com_content&view=article&id=40&Itemid=75 [accessed 25.08.12].
19. Kappetein A.P., Feldman T.E., Mack M.J., Morice M.-C., Holmes D.R., Stahle E., et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 2011, 32:2125-2134.
20. Raber L., Wohlwend L., Wigger M., Togni M., Wandel S., Wenaweser P., et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trial. Circulation 2011, 123:2819-2828.
21. Stone G.W. Comparison of Everolimus-Eluting (XIENCE V) and Paclitaxel-Eluting (TAXUS Express) stents: first report of the five-year clinical outcomes from the SPIRIT III trial. Presented at Transcatheter Cardiovascular Therapeutics 2011.
22. Claessen B.E., Beijk M.A., Legrand V., Ruzyllo W., Manari A., Varenne O., et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circulation 2009, 2:339-347.
23. Byrne R.A., Kastrati A., Massberg S., Wieczorek A., Laugwitz K.-L., Hadamitzky M., et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2011, 58:1325-1331.
24. Byrne R.A., Kastrati A., Tiroch K., Massberg S., Wieczorek, Laugwitz K., et al. Two-year outcomes after everolimus- or sirolimus-eluting stents in patients with coronary artery disease in the ISAR-TEST 4 trial. Presented at Transcatheter Cardiovascular Therapeutics 2010.
25. Park S.-J., Kang S.-J., Virmani R., Nakano M., Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol 2012, 59:2051-2057.
26. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
27. Brugaletta S., Radu M.D., Garcia-Garcia H.M., Heo J.H., Farooq V., Girasis C., et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?. Atherosclerosis 2012, 221:106-112.
28. Foerst J.R., Ball T.C., Nakano M., Virmani R., Kaplan A.V. Late complication: Xience V stent fractures with restenosis. JACC Cardiovasc Interv 2012, 5:239-242.
29. Valgimigli M., Campo G., Monti M., Vranckx P., Percoco G., Tumscitz C., et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012, 125:2015-2026.
30. Bittl J.A. Bioresorbable stents: the next revolution. Circulation 2010, 122:2236-2238.
31. Hofma S.H., van der Giessen W.J., van Dalen B.M., Lemos P.A., McFadden E.P., Sianos G., et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006, 27:166-170.
32. Togni M., Windecker S., Cocchia R., Wenaweser P., Cook S., Billinger M., et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005, 46:231-236.
33. Levine G.N., Bates E.R., Blankenship J.C., Bailey S.R., Bittl J.A., Cercek B., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011, 124:e574-e651. [Erratum appears in Circulation 2012 Feb 28;125(8):e412. Note: Dosage error in article text].
34. Task Force on Myocardial Revascularization of the European Society of Cardiology, The European Association for Cardio-Thoracic Surgery, European Association for Percutaneous Cardiovascular Interventions, Wijns W., Kolh P., Danchin N., et al. Guidelines on myocardial revascularization. Eur Heart J 2010, 31:2501-2555.
35. Nakazawa G., Finn A.V., Kolodgie F.D., Virmani R. A review of current devices and a look at new technology: drug-eluting stents. Expert Rev Med Devices 2009, 6:33-42.
36. Windecker S., Serruys P.W., Wandel S., Buszman P., Trznadel S., Linke A., et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008, 372:1163-1173.
37. Serruys P. LEADERS: five-year follow-up from a prospective, randomized trial of Biolimus A9-eluting stents with a biodegradable polymer vs. sirolimus-eluting stents with a durable polymer: final report of the LEADERS study. Presented at Transcatheter Cardiovascular Therapeutics 2012.
38. Raber L., Kelbaek H., Ostoijc M., Baumbach A., Heg D., Tuller D., et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012, 308:777-787.
39. Chevalier B., Silber S., Park S.-J., Garcia E., Schuler G., Suryapranata H., et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial - Phase 2. Circulation 2009, 2:188-195.
40. Ostoijc M., Beleslin S.D., Jung B., Persic R., Jagic Z., Nedljkovic N., et al. First clinical comparison of Nobori-Bioloimus A9 eluting stents with Cypher-Sirolimus eluting stents: NOBORI CORE nine months angiographic and one year clinical outcomes. EuroIntervention 2008, 3:574-579.
41. Smits P., van Boven A., Goy J.-J., den Heyer P., Serra A., Slagboom T., et al. COMPARE II trial. Presented at EuroPCR 2012.
42. Jeger R., Pfisterer M., Alber H., Eberli F., Galatius S., Naber C., et al. Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitats Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. Am Heart J 2012, 163. 136-41.e1.
43. Meredith I.T., Verheye S., Dubois C.L., Dens J., Fajadet J., Carrie D., et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol 2012, 59:1362-1370.
44. Han Y., Jing Q., Xu B., Yang L., Liu H., Shang X., et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv 2009, 2:303-309.
45. Han Y., Jing Q., Li Y., Yang L., Liu H., Shang X., et al. Sustained clinical safety and efficacy of a biodegradable-polymer coated sirolimus-eluting stent in "real-world" practice: three-year outcomes of the CREATE (Multi-Center Registry of EXCEL Biodegradable Polymer Drug Eluting Stents) study. Catheter Cardiovasc Interv 2012, 79:211-216.
46. Lemos P.A., Moulin B., Perin M.A., Oliveira L.A.R.R., Arruda J.A., Lima V.C., et al. Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial. EuroIntervention 2012, 8:117-119.
47. Lemos P.A., Moulin B., Perin M.A., Oliveira L.A.R.R., Arruda J.A., Lima V.C., et al. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial. Catheter Cardiovasc Interv 2009, 74:665-673.
48. Byrne R.A., Kastrati A., Kufner S., Massberg S., Birkmeier K.A., Laugwitz K.-L., et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009, 30:2441-2449.
49. Haude M. The REMEDEE study: insights from the angiographic and intravascular ultrasound comparison of a combination siroimus eluting EPC capture stent with a paclitaxel eluting stent. J Am Coll Cardiol 2012, 59:E209.
50. Guagliumi G., Sirbu V., Musumeci G., Bezerra H.G., Aprile A., Kyono H., et al. Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI). Circulation 2010, 3:367-375.
51. ClinicalTrials.gov. Biosensors Europe SA. Identifier: A Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug Coated Stent Versus the Gazelle Bare Metal Stent in Patients With High Risk of Bleeding. Last updated 19.06.12. Available at [accessed 28.09.12]. http://clinicaltrialsgov/ct2/show/NCT01623180%3Fterm=leaders+free%26rank=1.
52. Mehilli J., Kastrati A., Wessely R., Dibra A., Hausleiter J., Jaschke B., et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006, 113:273-279.
53. Mehilli J., Byrne R.A., Wieczorek A., Iijima R., Schulz S., Bruskina O., et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008, 29:1975-1982.
54. Byrne R.A., Kufner S., Tiroch K., Massberg S., Laugwitz K.L., Birkmeier A., et al. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 2009, 95:1489-1494.
55. Byrne R.A., Mehilli J., Iijima R., Schulz S., Pache J., Seyfarth M., et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009, 30:923-931.
56. Byrne R.A., Kastrati A., Tiroch K., Schulz S., Pache J., Pinieck S., et al. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. J Am Coll Cardiol 2010, 55:2536-2543.
57. Massberg S., Byrne R.A., Kastrati A., Schulz S., Pache J., Hausleiter J., et al. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation 2011, 124:624-632.
58. de Ribamar Costa J., Abizaid A., Costa R., Almeida B., Feres F., Perin M., et al. Two-year sustained efficacy of a novel, polymer-free sirolimus eluting stent: late results of the VESTASync II trial. J Am Coll Cardiol 2012, 59:E212.
59. Grube E. The BioFreedom DES: late results, technology challenges, and next steps. Presented at Global Summit on Innovations in Interventions 2012.
60. Serruys P.W., Onuma Y., Dudek D., Smits P.C., Koolen J., Chevalier B., et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011, 58:1578-1588.
61. Onuma Y., Ormiston J., Serruys P.W. Bioresorbable scaffold technologies. Circ J 2011, 75:509-520.
62. Ormiston J.A., Serruys P.W., Regar E., Dudek D., Thuesen L., Webster M.W.I., et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008, 371:899-907.
63. Ormiston J.A., Serruys P.W.S. Bioabsorbable coronary stents. Circulation 2009, 2:255-260.
64. Okamura T., Garg S., Gutierrez-Chico J.L., Shin E.-S., Onuma Y., Garcia-Garcia H.M., et al. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention 2010, 5:932-938.
65. Waksman R. The disappearing stent: when plastic replaces metal. Circulation 2012, 125:2291-2294.
66. Heublein B., Rohde R., Kaese V., Niemeyer M., Hartung W., Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology?. Heart 2003, 89:651-656.
67. Nishio S., Kosuga K., Igaki K., Okada M., Kyo E., Tsuji T., et al. Long-term (>10 years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation 2012, 125:2343-2353.
68. Verheye S. DESolve Myolimus Eluting Bioresorbable Coronary Scaffold First-in-Man Trial 6 month imaging and clinical results. Presented at EuroPCR 2012.
69. Haude M., Erbel R., Verheye S., Waksman R., Degen H., Bose D., et al. Twelve-month clinical and angiographic results of the multicenter first-in-man BIOSOLVE-1 study with the paclitaxel-eluting bioabsorbable magnesium scaffold. Presented at EuroPCR 2012.
70. ClinicalTrials.gov. REVA Medical, Inc. Identifier: Pilot Study of the ReZolve™ Sirolimus-Eluting Bioresorbable Coronary Stent. Last updated: 07.06.12. Available at [accessed 21.08.12]. http://clinicaltrialsgov/ct2/show/NCT01262703%3Fterm=reva%26rank=2.
71. ClinicalTrials.gov. Abbott Vascular. Identifier: ABSORB EXTEND Clinical Investigation: A Continuation in the Clinical Evaluation of the ABSORB Bioresorbable Vascular Scaffold (BVS) System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions. Last updated: 27.07.12. Available at [accessed 21.08.12]. http://clinicaltrialsgov/ct2/show/NCT01023789.
72. ClinicalTrials.gov. Abbott Vascular. Identifier: Absorb II Randomized Controlled Trial: A Clinical Evaluation to Compare the Safety, Efficacy and Performance of Absorb Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects With Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions. Last updated: 14.09.12. Available at [accessed 21.08.12]. http://clinicaltrialsgov/ct2/show/NCT01425281%3Fterm=bioresorbable+AND+scaffold+.
73. Dudek D., Onuma Y., Ormiston J.A., Thuesen L., Miquel-Hebert K., Serruys P.W. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 2012, 7:1060-1061.
74. Banning A. ABSORB clinical program - the latest!. Presented at EuroPCR 2012.
75. Serruys P.W., Ormiston J.A., Onuma Y., Regar E., Gonzalo N., Garcia-Garcia H.M., et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009, 373:897-910.
76. Serruys P., Onuma Y. 5-Year Cohort A and 2-year Cohort B results: integrated insights. Presented at Transcatheter Cardiovascular Therapeutics 2011.
77. Abizaide A., Bartorelli A., Whitbourn R., Clark L., Chevalier B., Miquel-Herbert K., et al. Preliminary data from ABSORB EXTEND: a report of the 6-month clinical outcomes from the first 200 patients enrolled. Presented at Transcatheter Cardiovascular Therapeutics 2011.
78. Elixir_Medical_Corporation_(online). DESolve Bioabsorbable Coronary Scaffold; 2012. Available at [accessed 24.08.12]. http://elixirmedicalcom/indexphp%3Fpage=ous-desolve.
79. Arterial_Remodelling_Technologies_(Online). ART products; 2012. Available at [accessed 24.08.12]. http://wwwart-stentcom/productsphp.
80. Onuma Y., Serruys P.W., Ormiston J.A., Regar E., Webster M., Thuesen L., et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 2010, 6:447-453.
81. Stefanini G.G., Byrne R.A., Serruys P.W., de Waha A., Meier B., Massberg S., et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012, 33:1214-1222.
82. Tamai H., Igaki K., Kyo E., Kosuga K., Kawashima A., Matsui S., et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000, 102:399-404.